Quantifying the Financial Return on Investment of Risk-Based Quality Management Implementation in Clinical Development
Therapeutic Innovation & Regulatory Science · 2026
DOI: 10.1007/s43441-026-01002-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2026. Verfasst von Abigail Dirks und 3 weiteren Autor:innen. Beteiligte Einrichtung: Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, MA, USA. Abigail.Dirks@tufts.edu. Hauptthemen laut MEDLINE: Drug Development, Risk Management. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CluePoints.
Abstract (Originalsprache)
Background
Despite widespread receptivity to risk-based quality management (RBQM) principles, adoption has been limited as drug development stakeholders have lacked quantitative evidence demonstrating return on investment (ROI).
Methods
Two assessments were conducted to estimate the ROI of RBQM. (1) Clinical trial level ROI was derived by analyzing monitoring cost efficiencies and clinical phase duration reductions under a 10% source data verification (SDV) scenario. (2) Program-level ROI was derived using an expected net present value (eNPV) modeling approach. Both analyses included data based on actual RBQM use in 18 recently completed oncology trials, as well as published and proprietary industry benchmarks.
Results
RBQM use was associated with reductions of 8–19% in clinical phase durations and monitoring cost reductions of up to 18% under a 10% SDV scenario. Total clinical trial ROIs ranged from $3.2 million (phase 1) to $18.9 million (phase 3), corresponding to ROI multiples of 6× to 23×. Program-level eNPV gains ranged from $3.8 million in phase 1 to $13.8 million in phase 3 corresponding to ROI multiples of 4× to 14×.
Conclusions
The ROI demonstrated at the individual clinical trial level and at the development program level provides a compelling business case for adopting RBQM particularly given alignment with ICH E6 R3 guidelines encouraging risk-based approaches supporting clinical trial planning and execution. Study findings indicate that RBQM-supported oversight not only improves data quality and risk detection but also represents a strategic investment that can help optimize resource allocation, increase development efficiency and speed, and enhance portfolio productivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, MA, USA. Abigail.Dirks@tufts.edu.
- Clue Points S.A, Louvain-la-Neuve, Belgium.
- CluePoints Inc, King of Prussia, PA, USA.
- Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, MA, USA.
ORCID-Profile: Abigail Dirks
Förderung
- CluePoints
Zitieren
APA
Dirks, A., de Viron, S., McFarlane, K., & Getz, K. A. (2026). Quantifying the Financial Return on Investment of Risk-Based Quality Management Implementation in Clinical Development. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-026-01002-1
Vancouver
Dirks A, de Viron S, McFarlane K, Getz KA. Quantifying the Financial Return on Investment of Risk-Based Quality Management Implementation in Clinical Development. Therapeutic Innovation & Regulatory Science. 2026. doi:10.1007/s43441-026-01002-1
BibTeX
@article{Dirks2026,
author = {Dirks, Abigail and de Viron, Sylviane and McFarlane, Kenneth and Getz, Kenneth A},
title = {Quantifying the Financial Return on Investment of Risk-Based Quality Management Implementation in Clinical Development},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2026},
doi = {10.1007/s43441-026-01002-1}
}
EUVIMED